Who
Gillian Cannon
Director
Company insider
Files Form 4 as: Director, Xenon Pharmaceuticals; Director, Corcept Therapeutics.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $126K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 1 Dec 2020
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $63K1,190 at $53.14 | filing |
| 5 Jun 2026filed 8 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $63K1,190 at $53.14 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 10 Sep 2025filed 11 Sep 2025 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code G | —7,393 at $0.00 | filing |
| 4 Sep 2025filed 8 Sep 2025 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —11,000 at $0.00 | filing |
| 4 Sep 2025filed 8 Sep 2025 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $253K11,000 at $22.99 | filing |
| 4 Sep 2025filed 8 Sep 2025 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $253K3,607 at $70.13 | filing |
| 10 Jun 2025filed 12 Jun 2025 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,012 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,645 at $0.00 | filing |
| 5 Jun 2024filed 5 Jun 2024 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,542 at $0.00 | filing |
| 17 May 2024filed 21 May 2024 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 10 Aug 2023filed 10 Aug 2023 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
News
Dr. Gillian Cannon Joins Lindus Therapeutics' Board as a Non-Executive Directorfinanznachrichten.de · 8 Sep 2026Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)XENE · dailypolitical.com · 18 Oct 2026Head to Head Survey: Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR)XENE · themarketsdaily.com · 12 Oct 2026Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Has Average Target Price of $70.27XENE · dailypolitical.com · 6 Oct 2026
1 headline in the last 90 days name Gillian Cannon; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.